Cryosite Posts 22% Revenue Growth and 41% EBITDA Increase in Q1 FY26

Robust Financial Performance Signals Momentum

Cryosite Limited has kicked off FY26 with impressive financial results, posting a 22% increase in revenue to $3.9 million and a 41% jump in EBITDA to $1.0 million for the first quarter ended September 30, 2025. These gains reflect the company’s expanding footprint in the highly specialised clinical trial logistics sector, where demand for temperature-controlled storage and distribution continues to accelerate.

Underlying this growth is a broad-based uplift across Cryosite’s key service segments. The Ambient, Cold, and Frozen division benefited from heightened activity in handling specialised commercial pharmaceutical products, diversifying beyond its traditional clinical trial clientele. Meanwhile, the Ultra-Frozen and Cryogenic segment, which supports cutting-edge cell and gene therapies as well as mRNA-based medicines, maintained strong momentum, bolstered by new biotech and research clients.

Strategic Capacity Expansion with New Warehouse

In a significant operational development, Cryosite is progressing with the acquisition of a freehold warehouse facility in Auburn, NSW, which will more than double its storage capacity. The company has secured a competitive debt facility from National Australia Bank to finance the purchase, with settlement expected in late November 2025. Immediate fit-out works will follow, enabling Cryosite to enhance its service offerings, scalability, and security through dual-site operations.

This expansion is timely, as Cryosite’s business development efforts continue to bear fruit. The company is onboarding several new clients monthly, including domestic and international subsidiaries and clinical trial sponsors. Long-standing clients are also renewing contracts and expanding their partnerships, particularly in the Cord Blood storage segment, which is transitioning from legacy upfront payment contracts to recurring annual agreements, thereby improving operating cash flows.

Industry Recognition and Future Outlook

Adding to the positive narrative, a recent commissioned report by RaaS Advisory highlighted Cryosite’s leadership in temperature-controlled storage and logistics within the life sciences and pharmaceutical industries. The report noted the rapid growth of Cryosite’s Ultra-Frozen and Cryogenic segment and pointed out the company’s attractive valuation relative to international peers.

Looking ahead, Cryosite enters Q2 FY26 with strong momentum and a clear strategic focus on scaling its Ultra-Frozen and Cryogenic operations alongside the new warehouse integration. As demand for compliant, high-integrity storage solutions intensifies, Cryosite appears well-positioned to capitalize on these trends and reinforce its reputation as a best-in-class partner in clinical trial logistics.